The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
 
Jennifer Cooperrider
Employment - Abbvie (I)
Stock and Other Ownership Interests - Abbvie (I)
 
Andrew Kin
No Relationships to Disclose
 
Jeffrey Zonder
No Relationships to Disclose
 
Anna Pula
No Relationships to Disclose
 
Frank Wen
No Relationships to Disclose
 
Ken Jiang
No Relationships to Disclose
 
Andrzej Jakubowiak
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi
 
Benjamin Derman
Honoraria - Multiple Myeloma Research Foundation; Plexus
Consulting or Advisory Role - Canopy Care; Cota Healthcare; Gerson Lehrman Group; Guidepoint Global; Janssen Scientific Affairs; Sanofi
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene